Menu
Image
Growth & Buyout
Regulatory & Product Launch
SERB SPECIALTY PHARMACEUTICALS acquires the rights from Ipsen to commercialize Xermelo® outside the US and Japan
Monday 4 April, 2022
Body
Xermelo® is indicated for the treatment of Carcinoid Syndrome Diarrhoea (CSD) in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. CSD is a debilitating condition that can be difficult to manage and severely impacts patients' quality of life.
Content
